In this issue:
Vedolizumab, adalimumab and infliximab for biliary inflammation
Immunosuppressant addition to anti-TNF-α monotherapy in IBD
Anti-TNF-α and immunosuppressant addition for CD
Gastrointestinal ultrasound in IBD in China
Late-onset rise of 6-MMP metabolites with thiopurines
Bax/Bcl-2 predicts response to infliximab in IBD
Safety of biological therapies in UC
Health concerns when travelling with IBD
Multidisciplinary team meetings effective in IBD management
Mechanism of selective IL-23 inhibition by risankizumab
Science blog: Bile acids, gut microbiome and IBD
Please login below to download this issue (PDF)